Level A· Stronger Clinical EvidenceMeta-analysisEurope PMCOpen access

The effect of bone marrow mesenchymal stem cell-derived extracellular vesicles on bone mineral density and microstructure in osteoporosis: A systematic review and meta-analysis of preclinical studies

Zhang Y., Xu X., Ren X., Li Z.

Meta-analysis, published in PLoS One (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
PLoS One (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40587472
PMCID
PMC12208419
DOI
10.1371/journal.pone.0327011

Abstract (original English)

Objective The treatment of osteoporosis is challenged by limited bone regeneration and side effects. Bone marrow mesenchymal stem cell-derived extracellular vesicles (BMSC-EVs) have gained widespread attention as a potential therapeutic approach. This study aims to evaluate the effects of BMSC-EVs on bone density, trabecular microstructure, and biomechanical properties in animal models of osteoporosis, providing evidence to support clinical translation and mechanism exploration. Methods A systematic search was conducted in the PubMed, Cochrane, Web of Science, and Embase (inception to January 2025) databases for preclinical studies on BMSC-EV intervention in osteoporosis models. A random-effects model was used to synthesize and analyze seven key parameters (BMD, BV/TV, Tb.N, Tb.Sp, Tb.Th, Ct.Th, and ultimate load-bearing capacity). Subgroup analysis was performed based on species (rats/mice), EVs engineering targets/methods, injection frequency, and treatment duration. The quality of the studies was assessed using SYRCLE's risk of bias tool. Results The meta-analysis of 10 studies (355 animals) showed that, compared to the control group, BMSC-EV treatment significantly increased BMD, BV/TV, Tb.N, Tb.Th, Ct.Th, and ultimate load-bearing capacity, while reducing Tb.Sp in the osteoporosis model. A publication bias was found in the summary analysis for Tb.N. However, sensitivity an

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Mesenchymal Stem CellsAnimalsHumansMiceRatsOsteoporosisDisease Models, AnimalBone DensityExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.